Patients with diagnostic CMR images for assessment of LGE/fibrosis and evidence/presence of non-ischaemic myocardial fibrosis/scar will be randomized to the following treatment groups in a 1:1 ratio: ICD group or Optimal HF care group.
NIDCM (idiopathic or familial)*
LVEF ≤35% and presence of fibrosis on CMR
Diagnostic CMR scan
Age ≥18 years
ICM [previous myocardial infarction, previous percutaneous coronary intervention]
Other cardiomyopathies (hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathies [e.g. cardiac amyloidosis, cardiac sarcoidosis, hemochromatosis and iron overload cardiomyopathy], left ventricular non-compaction cardiomyopathy, reversible cardiomyopathies [Takotsubo syndrrome, peripartum cardiomyopathy, chemotherapy induced cardiomyopathy].
Myocarditis
Contraindication for CMR at study entry (including severe claustrophobia, pacemaker or ICD, metallic cerebral or intracranial implants, known allergy to gadolinium)
Parallel
ICD/CRT-D implantation
Other interventionICD/CRT-D implantation (if indicated)
Death from any cause
Death from any causes during follow-up - after discharge.
Click on the lead sponsor to view all of their trials.
Prof. Dr. med. Ingo Eitel
Lead sponsor
University of Luebeck
Sponsor institution
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Collaborator
